PIKfyve: A Lipid Kinase & Therapeutic Target


PIKfyve: A Lipid Kinase & Therapeutic Target



PIKfyve, or PIP5K3, is a 5’ lipid kinase that produces two rare phosphoinositides, PI(5)P and PI(3,5)P2. Cellular synthesis of these two phospholipids controls signaling in the endosome-lysosome, and PIKfyve is implicated in several diseases. These include several types of cancer and neurodegenerative disorders. It has been predicted that Apilimod, a PIKfyve inhibitor, prevented SARS-CoV-2 entry into cells.

We, BTL Biotechno Labs Pvt. Ltd., are glad to inform you about the latest products launched by our principal partner Echelon Bioscience, Inc. : Z-RPK5 PIKfyve antibody and Z-RV14 Vac14 antibody.


PIKfyve (also known as PIP5K3) is a 237 kDa lipid kinase that primarily exists on early endosomes and synthesises PI(3,5)P2 from membrane-associated PI(3)P. Endosomal PIKfyve forms a complex with ArPIKfyve (Vac14) and Sac3 (FIG4) to regulate the fusion, transport, and export of endosomes in the cell.

Vac14, ArPIKfyve, is a scaffold protein that functions in a complex with PIKfyve and Sac3 (FIG4). This complex regulates the synthesis and turnover of phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2) on endosomal membranes.

@Echelon Bioscience, Inc is a global leader in academic research and pharmaceutical development biochemical reagents, assays, and peptides for academic research and pharmaceutical development. Echelon Biosciences offers the most comprehensive product range for lipid research worldwide. The company is engaged in the study of lipid signaling and critical metabolic enzymes, which provides new and viable targets for the development of potential drugs and diagnostics for cancer, diabetes, inflammation, infections, and cardiovascular disease.
For more details, please follow the below link: